Literature DB >> 19808576

Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study.

James H F Rudd1, Kelly S Myers, Sameer Bansilal, Josef Machac, Mark Woodward, Valentin Fuster, Michael E Farkouh, Zahi A Fayad.   

Abstract

BACKGROUND: Fluorodeoxyglucose positron-emission tomography (FDG PET) imaging of atherosclerosis has been used to quantify plaque inflammation and to measure the effect of plaque-stabilizing drugs. We explored how atherosclerotic plaque inflammation varies across arterial territories and how it relates to arterial calcification. We also tested the hypotheses that the degree of local arterial inflammation measured by PET is correlated with the extent of systemic inflammation and presence of risk factors for vascular disease. METHODS AND
RESULTS: Forty-one subjects underwent vascular PET/computed tomography imaging with FDG. All had either vascular disease or multiple risk factors. Forty subjects underwent carotid imaging, 27 subjects underwent aortic, 24 subjects iliac, and 13 subjects femoral imaging. Thirty-three subjects had a panel of biomarkers analyzed. We found strong associations between FDG uptake in neighboring arteries (left versus right carotid, r=0.91, P<0.001; ascending aorta versus aortic arch, r=0.88, P<0.001). Calcification and inflammation rarely overlapped within arteries (carotid artery FDG uptake versus calcium score, r=-0.42, P=0.03). Carotid artery FDG uptake was greater in those with a history of coronary artery disease (target-to-
BACKGROUND: <0.01) and in males versus females (target-to-
BACKGROUND: <0.05). Similar findings were also noted in the aorta and iliac arteries. Subjects with the highest levels of FDG uptake also had the greatest concentrations of inflammatory biomarkers (descending aorta target-to-
BACKGROUND: =0.53, P=0.01; carotid target-to-
BACKGROUND: =0.50, P=0.01). Nonsignificant positive trends were seen between FDG uptake and levels of interleukin-18, fibrinogen, and C-reactive protein. Finally, we found that the atheroprotective biomarker adiponectin was negatively correlated with the degree of arterial inflammation in the descending aorta (r=-0.49, P=0.03).
CONCLUSIONS: This study shows that FDG PET imaging can increase our knowledge of how atherosclerotic plaque inflammation relates to calcification, serum biomarkers, and vascular risk factors. Plaque inflammation and calcification rarely overlap, supporting the theory that calcification represents a late, burnt-out stage of atherosclerosis. Inflammation in one arterial territory is associated with inflammation elsewhere, and the degree of local arterial inflammation is reflected in the blood levels of several circulating biomarkers. We suggest that FDG PET imaging could be used as a surrogate marker of both atherosclerotic disease activity and drug effectiveness. Prospective, event-driven studies are now underway to determine the role of this technique in clinical risk prediction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808576      PMCID: PMC3190196          DOI: 10.1161/CIRCIMAGING.108.811752

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  33 in total

1.  Understanding the standardized uptake value, its methods, and implications for usage.

Authors:  Joseph A Thie
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

2.  Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores.

Authors:  Paul M Ridker; Nancy Cook
Journal:  Circulation       Date:  2004-03-29       Impact factor: 29.690

3.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

4.  Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption.

Authors:  I M Loftus; A R Naylor; S Goodall; M Crowther; L Jones; P R Bell; M M Thompson
Journal:  Stroke       Date:  2000-01       Impact factor: 7.914

5.  Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?

Authors:  H M Zhuang; A Cortés-Blanco; M Pourdehnad; L E Adam; A J Yamamoto; R Martínez-Lázaro; J H Lee; J C Loman; M D Rossman; A Alavi
Journal:  Nucl Med Commun       Date:  2001-10       Impact factor: 1.690

Review 6.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

7.  (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study.

Authors:  Mikako Ogawa; Seigo Ishino; Takahiro Mukai; Daigo Asano; Noboru Teramoto; Hiroshi Watabe; Nobuyuki Kudomi; Masashi Shiomi; Yasuhiro Magata; Hidehiro Iida; Hideo Saji
Journal:  J Nucl Med       Date:  2004-07       Impact factor: 10.057

8.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.

Authors:  Z S Galis; G K Sukhova; M W Lark; P Libby
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

9.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

10.  Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography.

Authors:  J H F Rudd; E A Warburton; T D Fryer; H A Jones; J C Clark; N Antoun; P Johnström; A P Davenport; P J Kirkpatrick; B N Arch; J D Pickard; P L Weissberg
Journal:  Circulation       Date:  2002-06-11       Impact factor: 29.690

View more
  88 in total

Review 1.  Multimodality cardiovascular molecular imaging technology.

Authors:  Matthew O'Donnell; Elliot R McVeigh; H William Strauss; Atsushi Tanaka; Brett E Bouma; Guillermo J Tearney; Michael A Guttman; Ernest V Garcia
Journal:  J Nucl Med       Date:  2010-05-01       Impact factor: 10.057

Review 2.  Imaging of coronary inflammation with FDG-PET: feasibility and clinical hurdles.

Authors:  Ian S Rogers; Ahmed Tawakol
Journal:  Curr Cardiol Rep       Date:  2011-04       Impact factor: 2.931

Review 3.  The year in molecular imaging.

Authors:  Eric A Osborn; Farouc A Jaffer
Journal:  JACC Cardiovasc Imaging       Date:  2010-11

4.  Impact of cardiovascular risk factors on vessel wall inflammation and calcified plaque burden differs across vascular beds: a PET-CT study.

Authors:  Frederik F Strobl; Axel Rominger; Sarah Wolpers; Carsten Rist; Fabian Bamberg; Kolja M Thierfelder; Konstantin Nikolaou; Christopher Uebleis; Marcus Hacker; Maximilian F Reiser; Tobias Saam
Journal:  Int J Cardiovasc Imaging       Date:  2013-08-24       Impact factor: 2.357

5.  Capping it off.

Authors:  H William Strauss
Journal:  J Nucl Cardiol       Date:  2009-07-25       Impact factor: 5.952

6.  Beyond stenosis: further progress in multi-modal evaluation of carotid disease.

Authors:  Gagandeep S Gurm; Ahmed Tawakol
Journal:  J Nucl Cardiol       Date:  2011-04       Impact factor: 5.952

7.  Noninvasive Positron Emission Tomography Imaging of Coronary Arterial Inflammation.

Authors:  Amr Abdelbaky; Ahmed Tawakol
Journal:  Curr Cardiovasc Imaging Rep       Date:  2011-02-01

Review 8.  Imaging the event-prone coronary artery plaque.

Authors:  Andreas A Giannopoulos; Dominik C Benz; Christoph Gräni; Ronny R Buechel
Journal:  J Nucl Cardiol       Date:  2017-07-06       Impact factor: 5.952

9.  Progress in atherosclerotic plaque imaging.

Authors:  Giulia Soloperto; Sergio Casciaro
Journal:  World J Radiol       Date:  2012-08-28

10.  Arterial inflammation in bronchial asthma.

Authors:  Jayanthi Vijayakumar; Sharath Subramanian; Parmanand Singh; Erin Corsini; Sara Fontanez; Meredith Lawler; Rebecca Kaplan; Thomas J Brady; Udo Hoffmann; Ahmed Tawakol
Journal:  J Nucl Cardiol       Date:  2013-03-23       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.